Publication

Go to Publication

Continue Reading ‘Universal’ access for MDR-TB limited without the involvement of the private sector.

Abstract BACKGROUND: There has been a recent surge in the recognition of interstitial lung disease (ILD) in India. METHODS: We conducted a retrospective study based on the available…

Continue Reading Retrospective study of interstitial lung disease in a tertiary care centre in India.

Go to Publication

Continue Reading Why “covering all” in the DOTS program is not necessarily “all being covered” by the DOTS program.

Abstract SETTING: Mumbai, India. A study conducted in Mumbai two decades ago revealed the extent of inappropriate tuberculosis (TB) management practices of private practitioners. Over the years, India's…

Continue Reading Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?

Abstract PURPOSE OF REVIEW: Pleural tuberculosis accounts for fewer than 1% of all exudative effusions in western countries, occurring in only 3-5% of tuberculous patients. However, in developing…

Continue Reading Pleural tuberculosis: an update.

Abstract BACKGROUND: India accounts for one-fifth of the global incident cases of tuberculosis(TB). The country presently has the world's largest directly observed treatment, short course (DOTS) programme, that…

Continue Reading Private patient perceptions about a public programme; what do private Indian tuberculosis patients really feel about directly observed treatment?

Abstract Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular…

Continue Reading Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

Go to Publication

Continue Reading Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective.